Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PTAFR Biologics Sequence Review Report 2026: Platelet-activating factor receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTAFR Biologics Sequence Review Report 2026: Platelet-activating factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTAFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR1F1 Biologics Sequence Review Report 2026: Olfactory receptor 1F1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR1F1 Biologics Sequence Review Report 2026: Olfactory receptor 1F1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR1F1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OXTR Biologics Sequence Review Report 2026: Oxytocin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OXTR Biologics Sequence Review Report 2026: Oxytocin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OXTR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR2A4 Biologics Sequence Review Report 2026: Olfactory receptor 2A4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR2A4 Biologics Sequence Review Report 2026: Olfactory receptor 2A4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR2A4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OPRL1 Biologics Sequence Review Report 2026: Nociceptin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OPRL1 Biologics Sequence Review Report 2026: Nociceptin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR1D2 Biologics Sequence Review Report 2026: Olfactory receptor 1D2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR1D2 Biologics Sequence Review Report 2026: Olfactory receptor 1D2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR1D2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OPRM1 Biologics Sequence Review Report 2026: Mu-type opioid receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OPRM1 Biologics Sequence Review Report 2026: Mu-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OPRK1 Biologics Sequence Review Report 2026: Kappa-type opioid receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OPRK1 Biologics Sequence Review Report 2026: Kappa-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OPRD1 Biologics Sequence Review Report 2026: Delta-type opioid receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OPRD1 Biologics Sequence Review Report 2026: Delta-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRD1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NTSR1 Biologics Sequence Review Report 2026: Neurotensin receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NTSR1 Biologics Sequence Review Report 2026: Neurotensin receptor type 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NTSR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NPY4R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NPY4R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPY4R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NPY2R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NPY2R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPY2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →